Results 141 to 150 of about 99,136 (277)

Unexplained Elevated Vitamin B12: Consider Macro‐B12

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Elevated vitamin B12 concentration can be caused by supplementation, liver disease, kidney disease, or myeloid malignancies. Persistent, unexplained elevations of vitamin B12 can raise concern among patients and may lead to invasive diagnostic procedures, including bone marrow biopsy.
Evelien G. E. Hurkmans   +3 more
wiley   +1 more source

Myelodysplastic syndrome [PDF]

open access: yesCanadian Medical Association Journal, 2016
Richard A, Wells   +2 more
openaire   +2 more sources

Patient‐Reported Oral Symptoms and Their Impact on Well‐Being After Haematopoietic Cell Transplantation

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective Oral complications may negatively influence outcomes of haematopoietic cell transplantation (HCT). A comprehensive view of oral symptoms and symptom burden post‐HCT is lacking. This study aimed to determine the prevalence, severity, and temporal relationships of oral symptoms and their impact on well‐being in the early post‐HCT phase.
Kristina Skallsjö   +14 more
wiley   +1 more source

Platelet Levels Associated With Bleeding Risk for Dental Interventions: A Systematic Review

open access: yesOral Diseases, EarlyView.
ABSTRACT Objectives To evaluate evidence in relation to postoperative bleeding in humans aged ≥ 16 with preoperative platelet counts < 50,000/μL, compared to those above, undergoing dental interventions. Methods Quantitative synthesis without meta‐analysis was conducted through an electronic search conducted on Ovid MEDLINE and Embase from 1946 to ...
Guang Xu David Lim   +3 more
wiley   +1 more source

Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series

open access: yesTransplant Infectious Disease, EarlyView.
This retrospective case series of acyclovir‐resistant HSV infection in pediatric patients undergoing allogeneic HSCT discusses the clinical course, associated complications, and treatment, including side effects. We propose the first algorithm for investigating and managing acyclovir‐resistant HSV infections in pediatric HSCT recipients, highlighting ...
Jenna Nunn   +9 more
wiley   +1 more source

A Case of Pancreatic Neuroendocrine Tumor Growing Intraductal Extension toward the Main Pancreatic Duct Complicated by Thrombocytopenia: Diagnostic Challenges and Management Strategy

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT We present a rare and diagnostically challenging case of a pancreatic neuroendocrine tumor (pNET) with intraductal growth into the main pancreatic duct (MPD), complicated by severe thrombocytopenia due to myelodysplastic syndrome. A 37‐year‐old male presented with thrombocytopenia.
Koichi Soga   +9 more
wiley   +1 more source

Incidence patterns and temporal trends of childhood cancer in Germany, 1980–2019: Forty years of childhood cancer registration in Germany

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1541-1554, 15 March 2026.
What's new? Childhood cancer ranks among the leading causes of disease‐related deaths in children in high‐income countries. Established risk factors, however, account for only a small proportion of incident childhood cancers. In this report, the authors present the first long‐term assessment of temporal trends in childhood cancer incidence rates in ...
Friederike Erdmann   +8 more
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman   +15 more
wiley   +1 more source

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes (LR‐MDS) in the COMMANDS Study

open access: yesAmerican Journal of Hematology, Volume 101, Issue 3, Page 427-438, March 2026.
ABSTRACT The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS ...
Rami S. Komrokji   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy